Pierre‐Michel Llorca

12.6k total citations · 2 hit papers
307 papers, 6.3k citations indexed

About

Pierre‐Michel Llorca is a scholar working on Psychiatry and Mental health, Clinical Psychology and Pharmacology. According to data from OpenAlex, Pierre‐Michel Llorca has authored 307 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Psychiatry and Mental health, 63 papers in Clinical Psychology and 55 papers in Pharmacology. Recurrent topics in Pierre‐Michel Llorca's work include Schizophrenia research and treatment (135 papers), Bipolar Disorder and Treatment (86 papers) and Treatment of Major Depression (50 papers). Pierre‐Michel Llorca is often cited by papers focused on Schizophrenia research and treatment (135 papers), Bipolar Disorder and Treatment (86 papers) and Treatment of Major Depression (50 papers). Pierre‐Michel Llorca collaborates with scholars based in France, United States and United Kingdom. Pierre‐Michel Llorca's co-authors include Christophe Lançon, Ludovic Samalin, Pascal Auquier, Laurent Boyer, I. de Chazeron, Guillaume Fond, Philippe Courtet, Georges Brousse, Olivier Blanc and Marion Leboyer and has published in prestigious journals such as New England Journal of Medicine, Journal of Neuroscience and SHILAP Revista de lepidopterología.

In The Last Decade

Pierre‐Michel Llorca

291 papers receiving 6.0k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

2023 110 citations Andreas Reif, Tetsuro Ito et al. profile →
Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial

2022 101 citations Wissam El‐Hage, Pierre‐Michel Llorca et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pierre‐Michel Llorca France	41	3.0k	1.7k	903	854	827	307	6.3k
Christophe Lançon France	43	3.0k 1.0×	1.9k 1.1×	406 0.4×	829 1.0×	734 0.9×	269	6.4k
Peter Haddad United Kingdom	44	4.8k 1.6×	1.6k 1.0×	528 0.6×	1.4k 1.7×	551 0.7×	180	7.9k
Robin Emsley South Africa	50	5.2k 1.7×	2.4k 1.4×	568 0.6×	746 0.9×	804 1.0×	281	8.5k
Dan Siskind Australia	45	3.3k 1.1×	2.4k 1.4×	713 0.8×	681 0.8×	332 0.4×	247	8.2k
James H. MacCabe United Kingdom	46	4.6k 1.5×	1.6k 0.9×	362 0.4×	532 0.6×	696 0.8×	219	7.6k
Fiona Gaughran United Kingdom	40	4.2k 1.4×	1.6k 1.0×	360 0.4×	416 0.5×	520 0.6×	198	8.4k
Paolo Girardi Italy	47	2.9k 1.0×	3.6k 2.1×	327 0.4×	711 0.8×	838 1.0×	212	7.3k
Ruud van Winkel Belgium	48	5.3k 1.7×	2.2k 1.3×	235 0.3×	836 1.0×	946 1.1×	201	9.1k
Massimo Di Giannantonio Italy	45	1.8k 0.6×	2.2k 1.3×	393 0.4×	886 1.0×	806 1.0×	207	5.8k
W. Wolfgang Fleischhacker Austria	64	7.2k 2.4×	2.1k 1.2×	708 0.8×	1.2k 1.4×	1.0k 1.3×	266	11.1k

Countries citing papers authored by Pierre‐Michel Llorca

Since Specialization

Citations

This map shows the geographic impact of Pierre‐Michel Llorca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre‐Michel Llorca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre‐Michel Llorca more than expected).

Fields of papers citing papers by Pierre‐Michel Llorca

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre‐Michel Llorca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre‐Michel Llorca. The network helps show where Pierre‐Michel Llorca may publish in the future.

Co-authorship network of co-authors of Pierre‐Michel Llorca

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre‐Michel Llorca. A scholar is included among the top collaborators of Pierre‐Michel Llorca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre‐Michel Llorca. Pierre‐Michel Llorca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vieta, Eduard, Celso Arango, Anthony J. Cleare, et al.. (2025). Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study. European Neuropsychopharmacology. 93. 29–39. 2 indexed citations

Edwards, Mark J., Pierre‐Michel Llorca, Maurice T. Driessen, et al.. (2025). Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review. European Psychiatry. 68(1). e115–e115.

Yrondi, Antoine, Hervé Javelot, Bénédicte Nobile, et al.. (2024). French Society for Biological Psychiatry and Neuropsychopharmacology (AFPBN) guidelines for the management of patients with partially responsive depression and treatment-resistant depression: Update 2024. L Encéphale. 51(1). 26–38. 7 indexed citations

Young, Allan H., Pierre‐Michel Llorca, Peter Falkai, et al.. (2024). Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial. The British Journal of Psychiatry. 226(2). 72–78.

Flaudias, Valentin, Corentin Gonthier, Marie Picot, et al.. (2023). Neuropsychological assessment fails to predict relapse among cigarette smokers: A prospective study of neurocognitive abilities. Addictive Behaviors. 151. 107940–107940. 1 indexed citations

Corponi, Filippo, Marion Leboyer, Frank Bellivier, et al.. (2023). Definition of early age at onset in bipolar disorder according to distinctive neurodevelopmental pathways: insights from the FACE-BD study. Psychological Medicine. 53(14). 6724–6732. 5 indexed citations

Lakbar, Inès, Marc Léone, Vanessa Pauly, et al.. (2023). Association of severe mental illness and septic shock case fatality rate in patients admitted to the intensive care unit: A national population-based cohort study. PLoS Medicine. 20(3). e1004202–e1004202. 10 indexed citations

Godin, Ophélia, Raoul Belzeaux, Bruno Aouizerate, et al.. (2022). Influence of childhood maltreatment on prevalence, onset, and persistence of psychiatric comorbidities and suicide attempts in bipolar disorders. European Psychiatry. 65(1). e15–e15. 12 indexed citations

Llorca, Pierre‐Michel, Philippe Nuss, É. Fakra, et al.. (2022). Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study. BMC Psychiatry. 22(1). 364–364. 2 indexed citations

10.

Hidalgo‐Mazzei, Diego, Olivier Blanc, Norma Verdolini, et al.. (2021). Patient and physician perspectives of a smartphone application for depression: a qualitative study. BMC Psychiatry. 21(1). 65–65. 24 indexed citations

11.

Etchecopar‐Etchart, Damien, Théo Korchia, Anderson Loundou, et al.. (2020). Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin. 47(2). 298–308. 58 indexed citations

12.

Fond, Guillaume, Xavier Zendjidjian, Karine Baumstarck, et al.. (2020). <p>Measuring the Patient Experience of Mental Health Care: A Systematic and Critical Review of Patient-Reported Experience Measures</p>. Patient Preference and Adherence. Volume 14. 2147–2161. 34 indexed citations

13.

Planche, Vincent, Fanny Munsch, Bruno Pereira, et al.. (2018). Anatomical predictors of cognitive decline after subthalamic stimulation in Parkinson’s disease. Brain Structure and Function. 223(7). 3063–3072. 14 indexed citations

14.

Chazeron, I. de, et al.. (2015). Alcohol Consumption for People Admitted in French Emergency Departments: A Protocol for a Multi-Center Cluster Trial. HAL (Le Centre pour la Communication Scientifique Directe). 5 indexed citations

15.

Djerada, Zoubir, et al.. (2015). Suivi thérapeutique pharmacologique de la clozapine. Therapies. 78(5). S67–S74. 5 indexed citations

16.

Garay, Ricardo P., Pierre‐Michel Llorca, Allan H. Young, Ahcène Hameg, & Ludovic Samalin. (2014). Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment. Drug Discovery Today. 19(11). 1792–1800. 10 indexed citations

17.

Corruble, Emmanuelle, Ellen Frank, Florence Gressier, et al.. (2013). Morningness–eveningness and treatment response in major depressive disorder. Chronobiology International. 31(2). 283–289. 34 indexed citations

18.

Brousse, Georges, Florence Vorspan, Martine Dubois, et al.. (2012). Alteration of Glutamate/GABA Balance During Acute Alcohol Withdrawal in Emergency Department: A Prospective Analysis. Alcohol and Alcoholism. 47(5). 501–508. 35 indexed citations

19.

Llorca, Pierre‐Michel & José‐Luis Fernández. (2007). Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. International Journal of Clinical Practice. 61(4). 702–710. 35 indexed citations

20.

Jm, Azorin, Pierre‐Michel Llorca, Nicolas Despiégel, & Patrice Verpillat. (2004). Traitement des épisodes dépressifs sévères : escitalopram est plus efficace que citalopram. L Encéphale. 30(2). 158–166. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact